Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IVVD with free AI briefings, catalyst countdowns, and dilution alerts.

IVVD · Invivyd, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$126.4M Cash on Hand
10.1mo Cash Runway
13.6% Short Interest
$10 Analyst Target (3)
Follow IVVD by email Get an email when IVVD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IVVD, unsubscribe in one click. Privacy

📣 What IVVD Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Adintrevimab (ADG20) COVID-19 Phase 2/3 · NCT04859517 Terminated
mRNA COVID-19 Vaccine COVID-19 Phase 3 · NCT07655180 Completed
VYD222 COVID-19 Phase 3 · NCT06039449 Completed
VYD2311 COVID-19 Phase 3 · NCT07655180 Completed
VYD2311-MD COVID-19 Phase 3 · NCT07298434 Active not recruiting
VYD2311-SD COVID-19 Phase 3 · NCT07298434 Active not recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IVVD holds $126.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $37.6M/quarter from operations, an estimated runway of 10.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IVVD files for a raise →

👥 Who Owns IVVD

Insiders 11.2% Institutions (185 holders) 87.5% Public and other holders 1.3%
HolderTypeShares% of sharesAs of
Janus Henderson Group Ltd. Institution (13F) 35,996,902 12.21% 2026-09-30
BVF PARTNERS L P/IL Institution (13G, 5%+) 29,571,826 10.03% 2026-06-30
BVF Inc. Institution (13F) 28,165,000 9.56% 2026-09-30
Maverick Capital, Ltd. Institution (13G, 5%+) 24,442,160 8.29% 2026-09-30
RA Capital Management, L.P. Institution (13G, 5%+) 21,342,442 7.24% 2026-03-31
Adimab, LLC
10% owner
Insider 20,262,170 6.87% 2025-12-23
BlackRock, Inc. Institution (13G, 5%+) 16,124,696 5.47% 2026-06-30
Perceptive Advisors Llc Institution (13F) 13,762,637 4.67% 2026-09-30
Ajay Royan
Director · +158,219 options
Insider 11,241,580 3.81% 2025-03-22
Vanguard Capital Management LLC Institution (13F) 10,979,581 3.72% 2026-09-30
M28 Capital Management LP Institution (13F) 9,248,250 3.14% 2026-09-30
Soleus Capital Management, L.P. Institution (13F) 7,524,958 2.55% 2026-09-30

Share count 294,758,746 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-08-31
filed 2026-09-02
Sheffield Ian
Option award (A) 100,000 – –
2026-08-30
filed 2026-09-01
Elia Marc
Option award (A) 10,700,000 – –
2026-08-18
filed 2026-08-18
Lee Timothy Edward
Sale (S) 18,425 $0.84 178,937
2026-08-18
filed 2026-08-18
Green Julie
Sale (S) 18,425 $0.84 168,937
2026-08-18
filed 2026-08-18
Andersen Jill
Sale (S) 30,706 $0.84 283,774

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full IVVD picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IVVD and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.